TY - JOUR
T1 - Elucidating the genetic architecture of Adams–Oliver syndrome in a large European cohort
AU - Meester, Josephina A.N.
AU - Sukalo, Maja
AU - Schröder, Kim C.
AU - Schanze, Denny
AU - Baynam, Gareth
AU - Borck, Guntram
AU - Bramswig, Nuria C.
AU - Duman, Duygu
AU - Gilbert-Dussardier, Brigitte
AU - Holder-Espinasse, Muriel
AU - Itin, Peter
AU - Johnson, Diana S.
AU - Joss, Shelagh
AU - Koillinen, Hannele
AU - McKenzie, Fiona
AU - Morton, Jenny
AU - Nelle, Heike
AU - Reardon, Willie
AU - Roll, Claudia
AU - Salih, Mustafa A.
AU - Savarirayan, Ravi
AU - Scurr, Ingrid
AU - Splitt, Miranda
AU - Thompson, Elizabeth
AU - Titheradge, Hannah
AU - Travers, Colm P.
AU - Van Maldergem, Lionel
AU - Whiteford, Margo
AU - Wieczorek, Dagmar
AU - Vandeweyer, Geert
AU - Trembath, Richard
AU - Van Laer, Lut
AU - Loeys, Bart L.
AU - Zenker, Martin
AU - Southgate, Laura
AU - Wuyts, Wim
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Adams–Oliver syndrome (AOS) is a rare developmental disorder, characterized by scalp aplasia cutis congenita (ACC) and transverse terminal limb defects (TTLD). Autosomal dominant forms of AOS are linked to mutations in ARHGAP31, DLL4, NOTCH1 or RBPJ, while DOCK6 and EOGT underlie autosomal recessive inheritance. Data on the frequency and distribution of mutations in large cohorts are currently limited. The purpose of this study was therefore to comprehensively examine the genetic architecture of AOS in an extensive cohort. Molecular diagnostic screening of 194 AOS/ACC/TTLD probands/families was conducted using next-generation and/or capillary sequencing analyses. In total, we identified 63 (likely) pathogenic mutations, comprising 56 distinct and 22 novel mutations, providing a molecular diagnosis in 30% of patients. Taken together with previous reports, these findings bring the total number of reported disease variants to 63, with a diagnostic yield of 36% in familial cases. NOTCH1 is the major contributor, underlying 10% of AOS/ACC/TTLD cases, with DLL4 (6%), DOCK6 (6%), ARHGAP31 (3%), EOGT (3%), and RBPJ (2%) representing additional causality in this cohort. We confirm the relevance of genetic screening across the AOS/ACC/TTLD spectrum, highlighting preliminary but important genotype–phenotype correlations. This cohort offers potential for further gene identification to address missing heritability.
AB - Adams–Oliver syndrome (AOS) is a rare developmental disorder, characterized by scalp aplasia cutis congenita (ACC) and transverse terminal limb defects (TTLD). Autosomal dominant forms of AOS are linked to mutations in ARHGAP31, DLL4, NOTCH1 or RBPJ, while DOCK6 and EOGT underlie autosomal recessive inheritance. Data on the frequency and distribution of mutations in large cohorts are currently limited. The purpose of this study was therefore to comprehensively examine the genetic architecture of AOS in an extensive cohort. Molecular diagnostic screening of 194 AOS/ACC/TTLD probands/families was conducted using next-generation and/or capillary sequencing analyses. In total, we identified 63 (likely) pathogenic mutations, comprising 56 distinct and 22 novel mutations, providing a molecular diagnosis in 30% of patients. Taken together with previous reports, these findings bring the total number of reported disease variants to 63, with a diagnostic yield of 36% in familial cases. NOTCH1 is the major contributor, underlying 10% of AOS/ACC/TTLD cases, with DLL4 (6%), DOCK6 (6%), ARHGAP31 (3%), EOGT (3%), and RBPJ (2%) representing additional causality in this cohort. We confirm the relevance of genetic screening across the AOS/ACC/TTLD spectrum, highlighting preliminary but important genotype–phenotype correlations. This cohort offers potential for further gene identification to address missing heritability.
KW - Adams–Oliver syndrome
KW - genetics
KW - mutation screening
KW - Notch signaling
KW - Rho GTPase
UR - http://www.scopus.com/inward/record.url?scp=85050869139&partnerID=8YFLogxK
U2 - 10.1002/humu.23567
DO - 10.1002/humu.23567
M3 - Article
C2 - 29924900
AN - SCOPUS:85050869139
SN - 1059-7794
VL - 39
SP - 1246
EP - 1261
JO - Human Mutation
JF - Human Mutation
IS - 9
ER -